BOCK

General

Botox for Underarm Sweating Works. How It Compares With Longer-Lasting Treatments Is the Open Question.

In 1875, Gustave Caillebotte painted The Floor Scrapers. Three men, stripped to the waist, kneel on a bare parquet floor and scrape it with iron blades. The Salon jury refused the picture that year, and it was shown with the Impressionists the following year. Nobody who looks at it thinks the men have a sweating problem. Their bodies are working, and the heat is the honest cost of the work.

Patients who come to me about their underarms describe the same wet shirt without the work. Many ask about Botox for underarm sweating, which doctors call axillary hyperhidrosis, and whether an injection can switch it off.

Three papers are worth knowing: a 2025 meta-analysis and a 2021 meta-analysis of randomized trials, both in Aesthetic Plastic Surgery, and a 2024 within-patient randomized trial in JAAD International.


Does Botox work for underarm sweating? What the pooled trials show

Yes. In pooled randomized trials, botulinum toxin reduced underarm sweat and improved daily life compared with saline (Obed et al., 2021). The 2021 meta-analysis pooled eight placebo-controlled trials with 937 patients, searched to August 2020. Six trials treated the armpit, one the face and one a residual limb. Six used botulinum toxin type A and two used type B (Obed et al., 2021).

In the armpit trials, the share of patients whose sweat fell by at least half, measured by weighing absorbent paper before and after (gravimetry), was higher with toxin than with saline. The risk difference was 0.63 (95% CI 0.51 to 0.76; five trials) (Obed et al., 2021). A risk difference is the gap between two proportions, so 0.63 means about 63 more patients in 100 reached the target with toxin. Across four trials, the share improving by at least two points on the Hyperhidrosis Disease Severity Scale, a patient rating of how much sweat disrupts daily activity, was higher by 0.56 (95% CI 0.42 to 0.69). On the Dermatology Life Quality Index, a questionnaire about how a skin problem affects life, scores improved by a mean of 5.55 points more than with saline (95% CI −7.11 to −3.98; four trials) (Obed et al., 2021).

A 2025 meta-analysis of 12 randomized trials with 904 patients with primary axillary hyperhidrosis agrees on direction. Against placebo, botulinum toxin type A reduced sweat on gravimetric testing, with no disagreement between the three placebo-controlled trials (I² = 0%) (Sun et al., 2025). I² describes how much trials disagree with each other, and 0% means little. The journal assigned this review level I evidence (Sun et al., 2025).


How long does one round of Botox for underarm sweating last?

The trials give a range rather than a number, from at least 14 weeks to about 31 weeks. In the 2025 meta-analysis, only three studies reported how long the effect was maintained: at least 14 weeks, at least 16 weeks, and 30.6 weeks (range 15.4 to 51.3) (Sun et al., 2025). The authors list long-term maintenance as a gap (Sun et al., 2025). The 2021 meta-analysis followed patients for about eight weeks and had no long-term efficacy data (Obed et al., 2021).

The 2024 trial adds a puzzle. Gravimetric sweat was still reduced by a median of 79% at one year in the armpit treated with toxin (Grove et al., 2024). The authors note that the one-year visit may not have let the toxin wear off completely (Grove et al., 2024). I would not read that figure as a promise of a year of relief.


Botox or a device for underarm sweating? What head-to-head data exist

There is one within-patient randomized trial of toxin against microwave thermolysis, and it found no significant difference in sweat reduction at one year (Grove et al., 2024). Thirty adults with primary axillary hyperhidrosis received botulinum toxin A (50 to 100 units per armpit) in one armpit and microwave thermolysis, a device that heats the tissue around the sweat glands (the study used the miraDry system), in the other. Sides were assigned at random (Grove et al., 2024).

At six months, the median sweat reduction was 74% with toxin and 58% with the device, a difference in favor of toxin (P = .0053). At one year it was 79% against 73% (P = .4282, not significant). Severity scores improved on both sides (Grove et al., 2024). The differences lay elsewhere. At one year the device side showed visible hair reduction (median score 2) and the toxin side none. Odor scores, which started at a median of 6.5 on both sides, were lower on the device side at one year (2.5 against 4; between-side P = .0098). Injection pain was higher with toxin (median 4.5 against 3 out of 10; P < .0001), and at the end 23 patients (76%) preferred the device and 5 (17%) preferred toxin (Grove et al., 2024).

The 2025 meta-analysis pooled trials comparing toxin with other treatments, including microwave thermolysis, 20% aluminum chloride, iontophoresis and fractional microneedle radiofrequency. The sweat reduction difference was not significant (difference 26.14; 95% CI −26.8 to 79.07; P = 0.33; four trials), and neither was the difference in severity scores (Sun et al., 2025). Not significantly different is not the same as equal, and these comparisons were few and varied.


Is Botox for underarm sweating safe?

No serious harms were reported in these papers, but injection pain is real and the safety numbers are thin. In the 2025 meta-analysis, adverse events in toxin groups included infection or common cold (14 events), sweating in other areas of the body (12), headache (4), itching (3) and shoulder girdle soreness (2). No study reported botulinum toxin poisoning or allergic shock, and pain was the main complaint (Sun et al., 2025). These are event counts, not rates. The 2024 trial reported no serious or unexpected adverse events (Grove et al., 2024).

The 2021 meta-analysis gave no pooled event counts. It described a substantial safety profile, noted that injection pain in the armpits can affect comfort and willingness to continue, and flagged muscle atrophy with fat deposition inside the muscle as a risk to discuss (Obed et al., 2021).


The strongest objection

Some will say the matter is settled. Two meta-analyses and a randomized trial all favor botulinum toxin, and it is a well-known injection. That is partly true. The direction of the effect is consistent against placebo (Obed et al., 2021; Sun et al., 2025).

But these papers share weaknesses. The 2021 meta-analysis found mixed, mostly moderate risk of bias, three sponsored trials and follow-up of about eight weeks, and its abstract and results give slightly different intervals for the same sweat outcome (Obed et al., 2021). The 2025 meta-analysis reported high heterogeneity on most outcomes and contains figures that do not reconcile, such as two different pain estimates (Sun et al., 2025). I did not check how many trials the two meta-analyses share, so they should not be counted as independent votes. The 2024 trial had 30 patients, one treating clinician, no blinding, and equipment supplied by the device manufacturer (Grove et al., 2024).


What should you ask before treating underarm sweat?

Ask first what the goal is: less sweat, less odor, or fewer months between treatments. The trials enrolled people with primary axillary hyperhidrosis and excluded generalized sweating and sweat-affecting medications (Grove et al., 2024), so a clinician should confirm that your sweating fits that picture before relying on these results.

Then ask how the options differ for you. Toxin reduced sweat, but it hurt more on injection, and the device left visible hair reduction and lower odor scores at one year in the one trial that compared them (Grove et al., 2024). Ask about the dose and how long relief is expected to last, since the trials gave a range (Sun et al., 2025), and ask what happens if sweating moves to another area.


The Clinical Bottom Line

Botulinum toxin is a reasonable, well-supported option for underarm sweating. Pooled randomized trials found more patients with at least a 50% drop in sweat than with saline (Obed et al., 2021), the 2025 review confirmed the direction against placebo (Sun et al., 2025), and the papers reported no serious harms such as poisoning or allergic shock.

The caution is about comparison and duration. The evidence for choosing between toxin and longer-lasting devices rests on one 30-patient trial, and the estimates of how long a single round lasts vary (Grove et al., 2024; Sun et al., 2025). What we still lack are larger head-to-head trials with long follow-up and blinded assessment.

Caillebotte's men sweat because they are working, and no one asks them to stop. Patients with excessive underarm sweat are working only to get through the day, and they deserve a treatment plan that says plainly how long it will last.

For clinical assessments and consultation in Seoul: itsdrbock.com

Cover image: The Floor Scrapers, Gustave Caillebotte (1875). Public domain. Source: Wikimedia Commons


References

Grove, G. L., Togsverd-Bo, K., Zachariae, C., & Haedersdal, M. (2024). Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis: A randomized controlled trial. JAAD International, 15, 91–99. https://doi.org/10.1016/j.jdin.2023.12.011

Obed, D., Salim, M., Bingoel, A. S., Hofmann, T. R., Vogt, P. M., & Krezdorn, N. (2021). Botulinum toxin versus placebo: A meta-analysis of treatment and quality-of-life outcomes for hyperhidrosis. Aesthetic Plastic Surgery, 45(4), 1783–1791. https://doi.org/10.1007/s00266-021-02140-7

Sun, J., Chen, S., Yang, T., Huang, L., Tang, J., Feng, Y., Yu, Q., Wang, Y., Luo, Y., Tang, Y., & Gao, L. (2025). Efficacy and safety of botulinum toxin type A in primary axillary hyperhidrosis: A meta-analysis and systematic review. Aesthetic Plastic Surgery, 49(17), 4932–4940. https://doi.org/10.1007/s00266-025-04909-6

More From the Blog